Felixvet Introduces Atipamezole Hydrochloride Injection for Reversal of Sedation and Analgesia in Dogs
Kansas City, Mo. — July 2, 2026 — Felixvet Inc. today announced the commercial availability of Atipamezole Hydrochloride Injection, a sterile injectable solution indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs. Atipamezole Hydrochloride Injection provides veterinarians with an FDA-approved option to support recovery following sedation procedures and expands Felixvet’s growing portfolio of companion animal pharmaceuticals.
Product Details
“Veterinarians rely on predictable recovery protocols following sedation procedures, and Atipamezole Hydrochloride Injection provides an important FDA-approved option for reversing the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to expand our injectable portfolio and continue providing veterinary professionals with high-quality treatment options that support patient care throughout the procedural process.”
Atipamezole Hydrochloride Injection is indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs. The product is intended for intramuscular administration and is designed to support recovery following the use of these commonly utilized sedative agents.
Atipamezole Hydrochloride Injection is available as a 5.0 mg/mL sterile injectable solution supplied in a 10 mL multidose vial.
The product is approved for intramuscular use in dogs and is therapeutically equivalent to the pioneer product, providing the same safety and efficacy profile. As a reversal agent, Atipamezole Hydrochloride Injection serves as an important component of veterinary sedation protocols by helping veterinarians manage patient recovery following sedation procedures.
Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.
For additional information, please contact info@felixvet.com
About Felixvet
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.
Media Contact
Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com
Related Articles
Felixvet Introduces Clomipramine Hydrochloride Tablets for the Treatment of Separation Anxiety in Dogs
Felixvet announces the commercial availability of Clomipramine Hydrochloride Tablets, an FDA-approved treatment for separation anxiety in dogs used...
Read Article Felixvet Expands Companion Animal Portfolio with Clindamycin Hydrochloride Tablets
Felixet expands its companion animal portfolio with FDA-approved Clindamycin Hydrochloride Tablets for treating bacterial infections in dogs
Read Article Felixvet Introduces Dexmedetomidine Hydrochloride Injectable Solution for Sedation, Analgesia, and Preanesthetic Use in Dogs and Cats
Felixvet announces the commercial availability of Dexmedetomidine Hydrochloride Sterile Injectable Solution 0.5 mg/mL, an FDA-approved sedative, analgesic, and...
Read Article